(Q42794495)

7 November 2017

In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp (English)

1 reference

7 November 2017

4

Ronald N Jones

1 reference

7 November 2017

Douglas J Biedenbach

1

1 reference

7 November 2017

James E Ross

series ordinal

2

1 reference

7 November 2017

Shannon D Putnam

series ordinal

3

1 reference

7 November 2017

language of work or name

English

0 references

publication date

22 March 2010

1 reference

Antimicrobial Agents and Chemotherapy

7 November 2017

1 reference

7 November 2017

54

1 reference

7 November 2017

5

1 reference

7 November 2017

2273-2275

1 reference

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

7 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

A case-control study of community-associated Clostridium difficile infection

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

Skin and environmental contamination with vancomycin-resistant Enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2863674

16 August 2018

Identifiers

DOI

10.1128/AAC.00090-10

1 reference

7 November 2017

1 reference

7 November 2017

PubMed publication ID

20308391

1 reference